Genenta Science S.p.A. (GNTA) Stock Analysis

What Genenta Science S.p.A. does

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

Key metrics

ETFs linked to GNTA

Broad-market and Healthcare sector ETFs an investor holding Genenta Science S.p.A. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GNTA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Genenta Science S.p.A.?

Genenta Science S.p.A. trades under the ticker GNTA on NASDAQ.

Which exchange is GNTA listed on?

GNTA is listed on NASDAQ.

What sector does Genenta Science S.p.A. operate in?

Genenta Science S.p.A. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GNTA in a portfolio?

PortView shows GNTA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.